Lineage Cell Therapeutics
LCTX
LCTX
129 hedge funds and large institutions have $88.4M invested in Lineage Cell Therapeutics in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 23 increasing their positions, 35 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
5.06% less ownership
Funds ownership: 47.89% → 42.83% (-5.1%)
34% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 35
Holders
129
Holding in Top 10
3
Calls
$676K
Puts
–
Top Buyers
| 1 | +$2.36M | |
| 2 | +$1.45M | |
| 3 | +$1.31M | |
| 4 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$731K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$430K |
Top Sellers
| 1 | -$8.34M | |
| 2 | -$1.86M | |
| 3 | -$1.63M | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.13M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$934K |
